Active, not recruitingPhase 1NCT04174105
Gene Transfer Study in Patients With Late Onset Pompe Disease
Studying Glycogen storage disease due to acid maltase deficiency, late-onset
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Astellas Gene Therapies
- Principal Investigator
- Medical DirectorAstellas Pharma Global Development, Inc.
- Intervention
- zocaglusagene nuzaparvovec(genetic)
- Enrollment
- 11 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2020 – 2035
Study locations (4)
- University of California Irvine, Department of Neurology, Orange, California, United States
- Stanford University, Palo Alto, California, United States
- University of Utah, Division of Medical Genetics, Salt Lake City, Utah, United States
- Newcastle Upon Tyne Hospitals Foundation Trust Clinical Research Facility, Newcastle upon Tyne, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04174105 on ClinicalTrials.govOther trials for Glycogen storage disease due to acid maltase deficiency, late-onset
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT06150820A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe DiseaseAstellas Gene Therapies
- RECRUITINGNANCT00567073Pompe Pregnancy Sub-RegistryGenzyme, a Sanofi Company
See all trials for Glycogen storage disease due to acid maltase deficiency, late-onset →